RGNX / REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead ca more_horizontal

REGENXBIO is a biotech company specializing in gene therapy, with a focus on addressing unmet medical needs in genetic disorders. The company's cash p more_horizontal

Regenxbio (RGNX) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1 more_horizontal

Regenxbio (NASDAQ:RGNX) Inc has one of the most-broad based approaches to adeno-associated virus (AAV)-based gene therapy (GT), utilizing their intell more_horizontal

ROCKVILLE, Md. , May 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conf more_horizontal

RegenxBio has several collaborations with other pharmaceutical companies. The company doesn't have its own wholly owned product but receives plenty of more_horizontal

ROCKVILLE, Md. , March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor co more_horizontal

REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Offic more_horizontal